Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis

Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis

IntroductionRecurrent allograft steatosis occurs in one-third of transplanted livers. Antidiabetic agents like glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter type-2 (SGLT2) inhibitors are effective in the management of obesity and hepatic steatosis in the general...

Full description

Bibliographic Details
Main Authors: Srilakshmi Atthota, Kayla Joyal, Mariesa Cote, Riley Scalzo, Ruby Singh, Nikita Consul, Aoife Kilcoyne, Emily D. Bethea, Leigh Anne Dageforde
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Transplantation
Subjects:
liver transplantation
obesity
metabolic syndrome
antidiabetic medication
weight loss
glucose-lowering medication
Online Access:https://www.frontiersin.org/articles/10.3389/frtra.2023.1223169/full

Internet

https://www.frontiersin.org/articles/10.3389/frtra.2023.1223169/full

Similar Items